Pathogenesis, Treatment and Prevention of Emerging Infectious Diseases

Lane, Henry C.

Abstract

Research in this project is currently focused on three areas. These are characterization of the survivors of the anthrax attacks of 2001;characterization of emerging respiratory infections including SARS and influenza;and development of novel therapies for flu. The anthrax study has enrolled a cohort of volunteers who are currently undergoing an extensive diagnostic evaluation. To be ready to deal with emerging infectious diseases of the respiratory tract, a protocol has been developed to systematically study patients presenting with a compatible symptom complex. This protocol has been complemented by the development of treatment protocols that will utilize hyperimmune plasma to the 2009 H1N1 virus or a combination of antiviral chemotherapeutic agents.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Allergy and Infectious Diseases (NIAID)
• Type: Investigator-Initiated Intramural Research Projects (ZIA)
• Project #: 1ZIAAI000936-09
• Application #: 8555879
• Support Year: 9
• Fiscal Year: 2012
• Total Cost: $171,956

Institution

• Name: National Institute of Allergy and Infectious Diseases

Publications

Davey Jr, Richard T; Dodd, Lori; Proschan, Michael et al. (2018) The Past Need Not Be Prologue: Recommendations for Testing and Positioning the Most-Promising Medical Countermeasures for the Next Outbreak of Ebola Virus Infection. J Infect Dis :

Kennedy, Stephen B; Bolay, Fatorma; Kieh, Mark et al. (2017) Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. N Engl J Med 377:1438-1447

Regules, Jason A; Beigel, John H; Paolino, Kristopher M et al. (2017) A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. N Engl J Med 376:330-341

Beigel, John H; Bao, Yajing; Beeler, Joy et al. (2017) Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. Lancet Infect Dis 17:1255-1265

Beigel, John H; Tebas, Pablo; Elie-Turenne, Marie-Carmelle et al. (2017) Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med 5:500-511

Dodd, Lori E; Proschan, Michael A; Neuhaus, Jacqueline et al. (2016) Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study. J Infect Dis 213:1906-13

Chertow, Daniel S; Nath, Avindra; Suffredini, Anthony F et al. (2016) Severe Meningoencephalitis in a Case of Ebola Virus Disease: A Case Report. Ann Intern Med 165:301-4

Lane, H Clifford; Marston, Hilary D; Fauci, Anthony S (2016) Conducting clinical trials in outbreak settings: Points to consider. Clin Trials 13:92-5

Kennedy, Stephen B; Neaton, James D; Lane, H Clifford et al. (2016) Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges. Clin Trials 13:49-56

Liddell, Allison M; Davey Jr, Richard T; Mehta, Aneesh K et al. (2015) Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United States. Ann Intern Med 163:81-90